On Tuesday the analysis results of a yearlong comparative study of hospital admission rates between diabetes patients using insulin pumps and those taking multiple daily injections of insulin were released by Medtronic (NYSE: MDT) and UnitedHealthcare (NYSE: UNH).
The FoI request was sent by enterprise IT firm Intercity Technology to as many as 143 NHS trusts in England. Out of these, 80 responded, of which 25 reported outages across their IT systems during the period from January 2015 to February 2018.
The healthcare sector has gained its entry into the new era of genomics and precision medicine. There are numerous health IT vendors, who offer to help healthcare providers by providing the right data with the objective of utmost patient care.
A study report published in Nature's Digital Medicine partner journal shows that the wearable monitor Fitbit Charge HR could assess the health condition of cancer patients and predict their adverse events.
Fatigue is a common complaint of chronic Hepatitis C sufferers. Fatigue is triggered by many factors, but insufficient sleep is considered to be the major cause and too many sleepless nights worsen the condition of Hepatitis C sufferers.
A woman aged 44 years old continuous pain in her left arm and shoulder. The doctors at the Royal Infirmary of Edinburgh in Scotland were unable to figure out the causative factor. Upon taking X-rays, they were astounded to find that the bones were disappearing. The woman was diagnosed with vanishing bone disease (Gorham-Stout disease).
Cerner and Lumeris have brought together their technologies to result in EHR agnostic. The Kansas City, Missouri-based Cerner specializes in EHRs and other IT solutions whereas the St. Louis, Missouri-based Lumeris’ technique involves value-based care.
Reports reveal that as many as 144,000 inmates of state prisons in the United States who have hepatitis C are not being given any kind of treatment. Corrections departments in every state were enquired about the number of inmates with hepatitis C, the treatment they were receiving, the drugs used for their treatment and also about policies that exist which concern inmates inflicted with the virus.
Gilead’s Yescarta and Novartis’ Kymriah garnered a lot of interest among T-cell therapies after producing high response rates in patients with lymphoma and leukemia. However, the same has not been true for this technology in cases of solid tumors. In this novel procedure, patients’ immune-boosting T cells are extracted and engineered to target and destroy cancer cells.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.